Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 8722-8732

  Brad Jones, R ^a   Yue, Feng Yun ^a   Gu, Xiao Xiao Jenny ^a   Hunter, Diana V ^a   Mujib, Shariq ^a   Gyenes, Gabor ^a   Mason, Rosemarie D ^a   Mohamed, Ruqaya ^a   MacDonald, Kelly S ^a,c   Kovacs, Colin ^a,b   Ostrowski, Mario A ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EPITOPE; GAG PROTEIN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; INTERLEUKIN 2; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEVIRAPINE; RECOMBINANT PROTEIN; TETRAMER; ZIDOVUDINE; IL2 PROTEIN, HUMAN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EPITOPE MAPPING; GENE SEQUENCE; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ANIMAL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MISSENSE MUTATION; SECRETION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2; LONGITUDINAL STUDIES; MALE; MUTATION, MISSENSE;

EID: 69249208673     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00433-09     Document Type: Article

References (45)

1. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
2. Anthony, D. D., and P. V. Lehmann. 2003. T-cell epitope mapping using the ELISPOT approach. Methods 29:260-269.
3. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339.
4. + T-cell-deficient mice. J. Virol. 68:4700-4704.
5. Bertoletti, A., A. Sette, F. V. Chisari, A. Penna, M. Levrero, M. De Carli, F. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407-410. (Pubitemid 24184055)
6. + CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169:6376-6385.
7. Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110. (Pubitemid 24258634)
8. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
9. + T cell memory. Science 297:2060-2063.
10. + T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 7:795-800.
11. Clark, S. J., M. S. Saag, W. D. Decker, S. Campbell-Hill, J. L. Roberson, P. J. Veldkamp, J. C. Kappes, B. H. Hahn, and G. M. Shaw. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324:954-960.
12. Daar, E. S., T. Moudgil, R. D. Meyer, and D. D. Ho. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-964.
13. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E. J. Wherry, H. M. Coovadia, P. J. Goulder, P. Klenerman, R. Ahmed, G. J. Freeman, and B. D. Walker. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354.
14. + T cells. Nature 417:95-98.
15. Gamble, T. R., S. Yoo, F. F. Vajdos, U. K. von Schwedler, D. K. Worthylake, H. Wang, J. P. McCutcheon, W. I. Sundquist, and C. P. Hill. 1997. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278:849-853. (Pubitemid 27467920)
16. Harcourt, G. C., S. Garrard, M. P. Davenport, A. Edwards, and R. E. Phillips. 1998. HIV-1 variation diminishes CD4 T lymphocyte recognition. J. Exp. Med. 188:1785-1793.
17. + T lymphocytes. Nature 421:852-856.
18. + cytotoxic T lymphocyte response. J. Exp. Med. 200:1243-1256.
19. Jones, R. B., L. C. Ndhlovu, J. D. Barbour, P. M. Sheth, A. R. Jha, B. R. Long, J. C. Wong, M. Satkunarajah, M. Schweneker, J. M. Chapman, G. Gyenes, B. Vali, M. D. Hyrcza, F. Y. Yue, C. Kovacs, A. Sassi, M. Loutfy, R. Halpenny, D. Persad, G. Spotts, F. M. Hecht, T. W. Chun, J. M. McCune, R. Kaul, J. M. Rini, D. F. Nixon, and M. A. Ostrowski. 2008. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205:2763-2779.
20. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246-1254.
21. Kaufmann, D. E., M. Lichterfeld, M. Altfeld, M. M. Addo, M. N. Johnston, P. K. Lee, B. S. Wagner, E. T. Kalife, D. Strick, E. S. Rosenberg, and B. D. Walker. 2004. Limited durability of viral control following treated acute HIV infection. PLoS Med. 1:e36.
22. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. Edwards, et al. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403-407. (Pubitemid 24184054)
23. + T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J. Acquir. Immune Defic. Syndr. 41:140-148.
24. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunode- ficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
25. Kovacs, J. A., S. Vogel, J. M. Albert, J. Falloon, R. T. Davey, Jr., R. E. Walker, M. A. Polis, K. Spooner, J. A. Metcalf, M. Baseler, G. Fyfe, and H. C. Lane. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350-1356.
26. + T cells. J. Exp. Med. 200:701-712.
27. Mammano, F., A. Ohagen, S. Hoglund, and H. G. Gottlinger. 1994. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68:4927-4936. (Pubitemid 24226558)
28. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056-8063.
29. + T cell proliferation. Proc. Natl. Acad. Sci. USA 98:13878-13883.
30. + T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 191:1921-1931.
31. +-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J. Virol. 78:14012-14022.
32. + T cell survival in HIV infection. J. Exp. Med. 203:2281-2292.
33. Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, C. R. Rizza, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459.
34. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890-1895.
35. + T cell responses associated with control of viremia. Science 278:1447-1450.
36. Sette, A., J. Alexander, J. Ruppert, K. Snoke, A. Franco, G. Ishioka, and H. M. Grey. 1994. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu. Rev. Immunol. 12:413-431.
37. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339. (Pubitemid 36433726)
38. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1-27.
39. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342.
40. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202.
41. Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral gag proteins. AIDS 5:639-654.
42. Wright, S. 1931. Evolution in Mendelian populations. Genetics 16:97-159.
43. + T cells endowed with proliferative capacity. J. Exp. Med. 198:1909-1922.
44. + T cells. J. Immunol. 174:2196-2204.
45. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.